CLINICAL TRIAL: BABY HUG

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 儿科羟基脲第三期临床试验羟基脲治疗幼儿的随机双盲安慰剂对照试验。在这项研究之前，将进行为期两年的内部试点研究。 参加内部试点研究和主要研究的所有儿童将接受为期104周的学习治疗。内部先导研究中的所有儿童将被跟踪，直到最后一个儿童S研究治疗结束，观察停止研究治疗的不良反应。研究治疗结束后，在研究治疗结束后的3个月、6个月、9个月、12个月、16个月、20个月、24个月和30个月继续进行后续诊所访问，并在此后每六个月进行一次后续诊所访问，最长可达五年。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Pediatric Hydroxyurea Phase III Clinical Trial; a Randomized Double-blind Placebo Controlled Trial of Hydroxyurea Therapy in Very Young Children. The study will be preceded by a two-year Internal Pilot Study. All the children enrolled in the Internal Pilot Study and the main study will receive study treatment for the duration of 104 weeks. All children in the Internal Pilot Study will be followed until the last child's study treatment has ended with observation for untoward effects of discontinuing study treatment. After study treatment ends, renewed consent will be requested for continued follow-up clinic visits at 3, 6, 9, 12, 16, 20, 24, and 30 months after the end of study treatment, and every six months thereafter for up to five years.